Merck & Co, Inc. (MRK) and Eisai Co. Ltd. announced Wednesday that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding their applications seeking accelerated approval of Merck's Keytruda, plus Eisai's Lenvima, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
from RTT - Biotech https://ift.tt/2DdrH5F
via IFTTT
No comments:
Post a Comment